Guardant Health withholds 17,087 co-CEO shares for taxes

Q: How many shares did Guardant Health co-CEO AmirAli Talasaz report withheld for taxes?

On September 30, 2026, 1,428 shares were withheld at $178.36 per share; on October 1, 2026, 17,087 shares were withheld at $174.75 per share. The company retained the shares to meet the award-holder’s tax withholding obligations, and the amount retained was not in excess of the tax liability.

Q: What vesting schedule applied to the 2,817 RSUs reported by Guardant Health co-CEO AmirAli Talasaz?

The award was granted March 17, 2026 and vests in four equal installments on the last day of each calendar quarter: March 31, June 30, September 30 and December 31, 2026.

Common shares from the reported awards were held by Talasaz and Eskandari 2017 Family Trust, while the company retained shares for tax withholding.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Guardant Health, Inc. co-CEO AmirAli Talasaz reported restricted stock unit conversions and common-share acquisitions by the Talasaz and Eskandari 2017 Family Trust. On September 30, 2026, 2,817 RSUs converted into 2,817 common shares held by the trust, and 1,428 shares were withheld for tax liability. On October 1, 2026, 23,997 and 9,716 RSUs converted into corresponding common shares held by the trust; 17,087 shares were withheld for tax liability.

Insider Trade Summary

36,530 shares exercised/converted

Exercise 8 txns

Insider Talasaz AmirAli

Role Co-Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units ^{F4, F3}	23,997	$0.00	$0.00
Exercise	Restricted Stock Units ^{F5, F3}	9,716	$0.00	$0.00
Exercise	Common Stock	23,997	$0.00	$0.00
Exercise	Common Stock	9,716	$0.00	$0.00
Tax Withholding	Common Stock ^F1	17,087	$174.75	$2.99M
Exercise	Restricted Stock Units ^{F2, F3}	2,817	$0.00	$0.00
Exercise	Common Stock	2,817	$0.00	$0.00
Tax Withholding	Common Stock ^F1	1,428	$178.36	$255K

Holdings After Transaction: Restricted Stock Units — 75,395 contracts (Direct); Common Stock — 1,842,366 shares (Indirect, Shares held by Talasaz and Eskandari 2017 Family Trust)

Footnotes (5)

F1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2. This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3. Not applicable for Restricted Stock Units.
F4. This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5. This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Key Figures

RSUs converted: 2,817 shares Common shares acquired by trust: 2,817 shares Shares withheld for tax liability: 1,428 shares +5 more

8 metrics

RSUs converted 2,817 shares September 30, 2026

Common shares acquired by trust 2,817 shares September 30, 2026

Shares withheld for tax liability 1,428 shares September 30, 2026; reported price $178.36 per share

RSUs converted 23,997 shares October 1, 2026

RSUs converted 9,716 shares October 1, 2026

Shares withheld for tax liability 17,087 shares October 1, 2026; reported price $174.75 per share

Reported price per share $178.36 per share 1,428 shares withheld on September 30, 2026

Reported price per share $174.75 per share 17,087 shares withheld on October 1, 2026

Key Terms

restricted stock units, tax withholding obligations, equal installments

3 terms

restricted stock units financial

"installment of the restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"meet the tax withholding obligations of the award-holder"

equal installments financial

"vests in four equal installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Guardant Health co-CEO AmirAli Talasaz report withheld for taxes?

On September 30, 2026, 1,428 shares were withheld at $178.36 per share; on October 1, 2026, 17,087 shares were withheld at $174.75 per share. The company retained the shares to meet the award-holder’s tax withholding obligations, and the amount retained was not in excess of the tax liability.

What vesting schedule applied to the 2,817 RSUs reported by Guardant Health co-CEO AmirAli Talasaz?

The award was granted March 17, 2026 and vests in four equal installments on the last day of each calendar quarter: March 31, June 30, September 30 and December 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/02/2026 - 04:59 PM Accepted by SEC EDGAR 10/02/2026 - 04:58 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Talasaz AmirAli

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Co-Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/30/2026		M		2,817	A	$0	1,827,168	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	09/30/2026		F		1,428⁽¹⁾	D	$178.36	1,825,740	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	10/01/2026		M		23,997	A	$0	1,849,737	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	10/01/2026		M		9,716	A	$0	1,859,453	I	Shares held by Talasaz and Eskandari 2017 Family Trust
Common Stock	10/01/2026		F		17,087⁽¹⁾	D	$174.75	1,842,366	I	Shares held by Talasaz and Eskandari 2017 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	09/30/2026		M			2,817	⁽²⁾	⁽³⁾	Common Stock	2,817	$0	2,817	D
Restricted Stock Units	$0	10/01/2026		M			23,997	⁽⁴⁾	⁽³⁾	Common Stock	23,997	$0	23,998	D
Restricted Stock Units	$0	10/01/2026		M			9,716	⁽⁵⁾	⁽³⁾	Common Stock	9,716	$0	48,580	D

Explanation of Responses:

1. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

2. This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.

3. Not applicable for Restricted Stock Units.

4. This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

5. This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR